血小板ADP受体P2Y12与凝血因子XIII基因多态性与冠心病的研究
|
摘要
第一部分
凝血因子ⅩⅢ-A Val34Leu基因多态性与冠心病、心肌梗死关系的研究
研究背景
目前凝血因子ⅩⅢ的Val34LCu基因多态性与冠心病、心肌梗死的关系研究报道仍存在许多争议,同时在亚洲人群中的研究较少。本文假设凝血因子ⅩⅢ-A亚单位Val34Leu基因多态性在中国汉族人群中存在,运用聚合酶链反应-单链核苷酸多态性(PCR-SSCP)的分子生物学方法,测定凝血因子ⅩⅢ的Val34Leu基因多态性,从而评价其在冠心病与心肌梗死中的作用。
研究内容:
本文调查了195例冠脉造影证实的冠心病患者与203例正常对照组的测定凝血因子ⅩⅢ的Val34Leu基因多态性。
本研究中在所有冠心病患者与正常对照组人群中我们没有发现Leu/Leu基因型.Val34Leu基因多态性在冠心病与正常对照组的分布没有显著性差异(P=0.923)。亚组分析中,把冠心病组患者根据有无心肌梗死再分为2组,统计分析发现Val/Leu基因型与心肌梗死的降低有关(P=0.005;校正odds ratio=1.75;95%可信区间=1.28-2.25)。同时,研究发现中国汉族人群中Leu34等位基因低于西方白种人群。
结论与创新:
本研究初步研究证实了中国汉族人群中存在凝血因子ⅩⅢVal34Leu基因多态性,但其分布频率低于西方白种人群。研究结果也加强了凝血因子Leu34等位基因是心肌梗死保护因子的可能性。同时凝血因子ⅩⅢVal34Leu基因多态性也许对心肌梗死后心肌愈合产生影响,而且存在其它的凝血因子ⅩⅢ的基因多态性。进一步的大规模临床研究与多中心的队列前瞻性研究应更注重于心肌梗死后心肌愈合过程的病理生理机制。
第二部分
血小板ADP受体P2Y12 H1/H2基因多态性与冠心病的研究
研究背景:
血小板在动脉粥样硬化斑块破裂后的血栓形成中起着重要的关键作用。斑块破裂与急性冠脉综合征(acute coronary syndromes,ACS)或冠脉介入手术(percutaneous coronary interventions,PCI)治疗的患者有密切关系。
在多种血小板激活的媒介物质中,二磷酸腺苷(adenosine diphosphate,ADP)尤为重要。二磷酸腺苷与血小板膜上相关受体结合,是凝血与血栓过程的重要中间物质。血小板激活后,二磷酸腺苷不仅从细胞类释放出来,而且可以激活血小板再活化,扩增整个血栓形成的过程。
血小板膜上有2个主要受体:1:GTP(guanosine triphosphate)偶联蛋白受体,也就是G-蛋白结合位点;2:铁通道受体(ligand-gated ion channel)2 R.F.Storey,L.J.Newby and S.Heptinstall,Effects of P2Y(1)and P2Y(12)receptor antagonists onplatelet aggregation induced by different agonists in human whole blood,Platelets 12(2001),后者受体称为P2X1,而前者称为P2Y。这2个受体在血小板激活与聚集过程中都起着重要的作用。
最近有研究报道在一组健康人群的实验中,血小板膜上P2Y12受体基因多态性被认为与血小板聚集率相关,而且与外周动脉疾病有关。本文测定了中国汉族人群中P2Y12受体的H1H2基因多态性的频率及与冠心病的关系。
研究内容:
观察冠状动脉造影患者血小板膜ADP受体P2Y12功能获得性基因多态性在分布及其与冠心病的关系,并探求该位点的突变与凝血酶的关系。
应用聚合酶链反应和限制性内切酶片段长度多态性技术检测了654例进行选择性冠状动脉造影患者的血小板膜上ADP受体P2Y12 H1/H2基因型,其中302例CAD患者和352例对照组,结合造影结果探讨该基因多态性和冠心病的关系。
ADP受体P2Y12 H1/H2基因多态性在本组人群中的分布频率为H1/H1 78.6%,H1/H2 19.7%,H2/H2 1.7%,等位基因为H1 88.5%,H2 11.5%.冠心病组为H1/H1223(73.8%),H1/H2 71(23.5%),H2/H2 8(2.7%),对照组为H1/H1 291(82.7%),H1/H2 58(16.5%)H2/H2 3(0.8%)基因型频率符合Hardy-Weinberg平衡定律,两者之间差异有显著性(χ2=8.808,P＜0.05)。等位基因为冠心病组H2 87(14.4%),H1517(85.6%),对照组H2 64(9.0%)H1640(90.1%),两者差异有显著性(χ2=8.987,P＜0.01).凝血酶中只有激活的部分凝血酶时间(APTT)与该位点的基因型有关。
结论与创新:
中国南方汉族人群中存在着ADP受体P2Y12 H1/H2的基因多态性,并且该多态性可能与冠心病的发生有关。
PartⅠCoagulation FactorⅩⅢ-A Val34Leu Polymorphism and the Risk of Coronary Artery Disease and Myocardial Infarction in A Chinese Han Population
Background
There are controversial data regarding the impact of coagulation factorⅩⅢ-A subunit(FⅩⅢ-A) Val34Leu polymorphism in the pathogeneric of coronary artery disease(CAD) and myocardial infarction(MI).Assuming this genetic factor is associated with the thrombotic process,we explored the role of FⅩⅢ-A Val34Leu in CAD and MI in a Chinese Han population.
Methods and Results
We recruited 195 consecutive CAD patients confirmed by coronary angiography as well as a group of 203 controls.FⅩⅢ-A Val34Leu polymorphism was determined through polymerase chain reaction-single strand conformational polymorphism analysis.
We did not find the Leu/Leu genotype in CAD patients or controls.No significant difference in Val34Leu gene polymorphism distribution was found between CAD patients and controls(P=0.923).Subgroup analysis according to history of MI showed the heterozygote Val/Leu genotype was associated with a significantly decreased risk of MI(P=0.005;adjusted odds ratio=1.75;95%confidence interval =1.28-2.25).Furthermore,our study displayed that the frequency of the Leu34 allele in a Chinese Han population was lower than that in Caucasian populations(2.5 vs. 20.4-28.3%).
Conclusion
Our preliminary data indicates that the FⅩⅢ-A Leu34 allele may contribute a protective effect against the development of MI.There is a low prevalence of the Leu34 allele in Han Chinese compared to Caucasians.
PARTⅡThe Association of ADP P2Y_(12) H1/H2 Polymorphism and Coronary Artery Disease
Background
Platelets play a key role in the pathophysiology of thrombosis after plaque rupture. Plaque rupture occurs spontaneously in patients with acute coronary syndromes(ACS), or may be induced in patients undergoing percutaneous coronary interventions(PCI).
Among the multiple mediators of platelet activation,adenosine diphosphate(ADP) plays a pivotal role.Adenosine diphosphate binds to several receptors on the platelet membrane.Adenosine diphosphate is one of the most important mediators of both physiological hemostasis and thrombosis.After platelet activation,ADP is not only released from its intracellular storage granules but also further activates platelets, amplifying this process.
There are 2 main purinergic receptor types in the membrane:the guanosine triphosphate(GTP)-coupled protein receptors,known as G-protein binding sites,and the ligand-gated ion channel.The latter receptor is designated P2X_1 and the former is designated as P2Y,and each play a specific and complimentary role in platelet activation and aggregation.
Recently,polymorphisms of the P2Y12 receptor have been associated with different degrees of platelet aggregation in healthy volunteers and also have been indicated to relate to artery disease.We investigate the P2Y12 receptor H1H2 gene polymorphism's frequency distribution and the association with coronary artery disease.
Methods and Results
To observe the frequencies of the polymorphism of Adenosine Diphosphate(ADP) Receptor P2Y12 H1/H2 Haplotype in Chinese and the relationship between the polymorphism and coronary artery disease(CAD).
ADP receptor P2Y12 H1/H2 Haplotype polymorphism was performed in 654 patients who were performed selective coronary angiography by using PCR-RFLP methods.The patients were classfied as 302 CAD patients group and 352 controls group.
It was observed the relationship between the polymorphism of ADP receptor P2Y12 H1/H2 Haplotype polymorphism.The frequencies of genotype were H1/H1 78.6%,H1/H2 19.7%,H2/H2 1.7%.The frequencies of allele was H1 88.5%,H2 11.5%.The genotype distribution was in accordance with Hardy- Weinberg equilibrilum.A significant increase was found for the ADP receptor P2Y12 H1/H2 in CAD patients compared with controls(26.2%vs17.3%,χ2=8.808,P＜0.05)。A significant increase was found for ADP receptor P2Y12 H1/H2 Haplotype H2 allele in CAD patients compared with controls(14.4%vs9.0%,χ2=8.987,P＜0.01).Only the relationship of the APTT and the genotype were observed in this study.
Conclusion
The polymorphism of ADP receptor P2Y12 H1/H2 Haplotype is present in Chinese and the H2 allele is a major risk factor for CAD patients.
凝血因子ⅩⅢ-A Val34Leu基因多态性与冠心病、心肌梗死关系的研究
研究背景
目前凝血因子ⅩⅢ的Val34LCu基因多态性与冠心病、心肌梗死的关系研究报道仍存在许多争议,同时在亚洲人群中的研究较少。本文假设凝血因子ⅩⅢ-A亚单位Val34Leu基因多态性在中国汉族人群中存在,运用聚合酶链反应-单链核苷酸多态性(PCR-SSCP)的分子生物学方法,测定凝血因子ⅩⅢ的Val34Leu基因多态性,从而评价其在冠心病与心肌梗死中的作用。
研究内容:
本文调查了195例冠脉造影证实的冠心病患者与203例正常对照组的测定凝血因子ⅩⅢ的Val34Leu基因多态性。
本研究中在所有冠心病患者与正常对照组人群中我们没有发现Leu/Leu基因型.Val34Leu基因多态性在冠心病与正常对照组的分布没有显著性差异(P=0.923)。亚组分析中,把冠心病组患者根据有无心肌梗死再分为2组,统计分析发现Val/Leu基因型与心肌梗死的降低有关(P=0.005;校正odds ratio=1.75;95%可信区间=1.28-2.25)。同时,研究发现中国汉族人群中Leu34等位基因低于西方白种人群。
结论与创新:
本研究初步研究证实了中国汉族人群中存在凝血因子ⅩⅢVal34Leu基因多态性,但其分布频率低于西方白种人群。研究结果也加强了凝血因子Leu34等位基因是心肌梗死保护因子的可能性。同时凝血因子ⅩⅢVal34Leu基因多态性也许对心肌梗死后心肌愈合产生影响,而且存在其它的凝血因子ⅩⅢ的基因多态性。进一步的大规模临床研究与多中心的队列前瞻性研究应更注重于心肌梗死后心肌愈合过程的病理生理机制。
第二部分
血小板ADP受体P2Y12 H1/H2基因多态性与冠心病的研究
研究背景:
血小板在动脉粥样硬化斑块破裂后的血栓形成中起着重要的关键作用。斑块破裂与急性冠脉综合征(acute coronary syndromes,ACS)或冠脉介入手术(percutaneous coronary interventions,PCI)治疗的患者有密切关系。
在多种血小板激活的媒介物质中,二磷酸腺苷(adenosine diphosphate,ADP)尤为重要。二磷酸腺苷与血小板膜上相关受体结合,是凝血与血栓过程的重要中间物质。血小板激活后,二磷酸腺苷不仅从细胞类释放出来,而且可以激活血小板再活化,扩增整个血栓形成的过程。
血小板膜上有2个主要受体:1:GTP(guanosine triphosphate)偶联蛋白受体,也就是G-蛋白结合位点;2:铁通道受体(ligand-gated ion channel)2 R.F.Storey,L.J.Newby and S.Heptinstall,Effects of P2Y(1)and P2Y(12)receptor antagonists onplatelet aggregation induced by different agonists in human whole blood,Platelets 12(2001),后者受体称为P2X1,而前者称为P2Y。这2个受体在血小板激活与聚集过程中都起着重要的作用。
最近有研究报道在一组健康人群的实验中,血小板膜上P2Y12受体基因多态性被认为与血小板聚集率相关,而且与外周动脉疾病有关。本文测定了中国汉族人群中P2Y12受体的H1H2基因多态性的频率及与冠心病的关系。
研究内容:
观察冠状动脉造影患者血小板膜ADP受体P2Y12功能获得性基因多态性在分布及其与冠心病的关系,并探求该位点的突变与凝血酶的关系。
应用聚合酶链反应和限制性内切酶片段长度多态性技术检测了654例进行选择性冠状动脉造影患者的血小板膜上ADP受体P2Y12 H1/H2基因型,其中302例CAD患者和352例对照组,结合造影结果探讨该基因多态性和冠心病的关系。
ADP受体P2Y12 H1/H2基因多态性在本组人群中的分布频率为H1/H1 78.6%,H1/H2 19.7%,H2/H2 1.7%,等位基因为H1 88.5%,H2 11.5%.冠心病组为H1/H1223(73.8%),H1/H2 71(23.5%),H2/H2 8(2.7%),对照组为H1/H1 291(82.7%),H1/H2 58(16.5%)H2/H2 3(0.8%)基因型频率符合Hardy-Weinberg平衡定律,两者之间差异有显著性(χ2=8.808,P＜0.05)。等位基因为冠心病组H2 87(14.4%),H1517(85.6%),对照组H2 64(9.0%)H1640(90.1%),两者差异有显著性(χ2=8.987,P＜0.01).凝血酶中只有激活的部分凝血酶时间(APTT)与该位点的基因型有关。
结论与创新:
中国南方汉族人群中存在着ADP受体P2Y12 H1/H2的基因多态性,并且该多态性可能与冠心病的发生有关。
PartⅠCoagulation FactorⅩⅢ-A Val34Leu Polymorphism and the Risk of Coronary Artery Disease and Myocardial Infarction in A Chinese Han Population
Background
There are controversial data regarding the impact of coagulation factorⅩⅢ-A subunit(FⅩⅢ-A) Val34Leu polymorphism in the pathogeneric of coronary artery disease(CAD) and myocardial infarction(MI).Assuming this genetic factor is associated with the thrombotic process,we explored the role of FⅩⅢ-A Val34Leu in CAD and MI in a Chinese Han population.
Methods and Results
We recruited 195 consecutive CAD patients confirmed by coronary angiography as well as a group of 203 controls.FⅩⅢ-A Val34Leu polymorphism was determined through polymerase chain reaction-single strand conformational polymorphism analysis.
We did not find the Leu/Leu genotype in CAD patients or controls.No significant difference in Val34Leu gene polymorphism distribution was found between CAD patients and controls(P=0.923).Subgroup analysis according to history of MI showed the heterozygote Val/Leu genotype was associated with a significantly decreased risk of MI(P=0.005;adjusted odds ratio=1.75;95%confidence interval =1.28-2.25).Furthermore,our study displayed that the frequency of the Leu34 allele in a Chinese Han population was lower than that in Caucasian populations(2.5 vs. 20.4-28.3%).
Conclusion
Our preliminary data indicates that the FⅩⅢ-A Leu34 allele may contribute a protective effect against the development of MI.There is a low prevalence of the Leu34 allele in Han Chinese compared to Caucasians.
PARTⅡThe Association of ADP P2Y_(12) H1/H2 Polymorphism and Coronary Artery Disease
Background
Platelets play a key role in the pathophysiology of thrombosis after plaque rupture. Plaque rupture occurs spontaneously in patients with acute coronary syndromes(ACS), or may be induced in patients undergoing percutaneous coronary interventions(PCI).
Among the multiple mediators of platelet activation,adenosine diphosphate(ADP) plays a pivotal role.Adenosine diphosphate binds to several receptors on the platelet membrane.Adenosine diphosphate is one of the most important mediators of both physiological hemostasis and thrombosis.After platelet activation,ADP is not only released from its intracellular storage granules but also further activates platelets, amplifying this process.
There are 2 main purinergic receptor types in the membrane:the guanosine triphosphate(GTP)-coupled protein receptors,known as G-protein binding sites,and the ligand-gated ion channel.The latter receptor is designated P2X_1 and the former is designated as P2Y,and each play a specific and complimentary role in platelet activation and aggregation.
Recently,polymorphisms of the P2Y12 receptor have been associated with different degrees of platelet aggregation in healthy volunteers and also have been indicated to relate to artery disease.We investigate the P2Y12 receptor H1H2 gene polymorphism's frequency distribution and the association with coronary artery disease.
Methods and Results
To observe the frequencies of the polymorphism of Adenosine Diphosphate(ADP) Receptor P2Y12 H1/H2 Haplotype in Chinese and the relationship between the polymorphism and coronary artery disease(CAD).
ADP receptor P2Y12 H1/H2 Haplotype polymorphism was performed in 654 patients who were performed selective coronary angiography by using PCR-RFLP methods.The patients were classfied as 302 CAD patients group and 352 controls group.
It was observed the relationship between the polymorphism of ADP receptor P2Y12 H1/H2 Haplotype polymorphism.The frequencies of genotype were H1/H1 78.6%,H1/H2 19.7%,H2/H2 1.7%.The frequencies of allele was H1 88.5%,H2 11.5%.The genotype distribution was in accordance with Hardy- Weinberg equilibrilum.A significant increase was found for the ADP receptor P2Y12 H1/H2 in CAD patients compared with controls(26.2%vs17.3%,χ2=8.808,P＜0.05)。A significant increase was found for ADP receptor P2Y12 H1/H2 Haplotype H2 allele in CAD patients compared with controls(14.4%vs9.0%,χ2=8.987,P＜0.01).Only the relationship of the APTT and the genotype were observed in this study.
Conclusion
The polymorphism of ADP receptor P2Y12 H1/H2 Haplotype is present in Chinese and the H2 allele is a major risk factor for CAD patients.
引文
1. Xu G, Jin GD, Fu GS, Ma J, Shi YP, Tang OS, Shan J. Polymorphisms in the genes for coagulation factor II, V, VII in patients undergoing coronary angiography. J. Zhejiang Uni. (Science). 2003; 4 (3): 369-73
2. Mikkola H, Syrjala M, Rasi V, Vahtera E, Hamalainen E, Peltonen L, Palotie A.Deficiency in the A-subunit of coagulation factor XIII: two novel point mutations demonstrate different effects on transcript levels. Blood. 1994; 84:517-25.
3. Balogh I, Szoke G, Karpati L, Wartiovaara U, Katona E, Komaromi I,Haramura G, Pfliegler G, Mikkola H, Muszbek L. Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia.Blood 2000; 96:2479-86.
4. Wartiovaara U, Mikkola H, Szoke G, Haramura G, Karpati L, Balogh I, Lassila R, Muszbek L, Palotie A. Effect of Val34Leu polymorphism on the activation of the coagulation factor XIII-A. Thromb Haemost 2000; 84: 595-600.
5. Ariens RA, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96: 988-95.
6. Lim BC, Ariens RA, Carter AM, Weisel JW, Grant PJ. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 2003; 361: 1424-31.
7. Lorand L, Losowsky MS, Miloszewski KJ. Human factor XIII:fibrin-stabilizing factor. Prog. Hemost. Thromb. 1980; 5:245-90.
8. Polgar J, Hidasi V, Muszbek L. Non-proteolytic activation of cellular protransglutaminase (placenta macrophage factor XIII). Biochem. J. 1990; 267:557-60.
9. Schwartz ML, Pizzo SV, Hill RL, McKee PA. Human factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and crosslinking of fibrinogen and fibrin. J. Biol. Chem. 1973; 248: 1395-407
10. Loukianos S. Rallidis, Marianna Politou, Christoforos Komporozos,Demosthenes B. Panagiotakos, Chrisoula I. Belessi, Anthi Travlou, John Lekakis, Dimitrios T. Kremastinos. Factor XIII Val34Leu polymorphism and the risk of myocardial infarction under the age of 36 years. Thromb. Haemost.2008; 99: 1085-9
11. Aleksic N, Ahn C, Wang YW. Factor XIIIA Val34Leu polymorphism does not predict risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler. Thromb. Vasc. Biol. 2002; 22:348-52.
12. Cho KH, Kim BC, Kim MK, Shin BA. No Association of Factor XIII Val34Leu Polymorphism with Primary Intracerebral Hemorrhage and Healthy Controls in Korean Population. J. Korean. Med. Sci. 2002; 17: 249-53.
13. Suzuki K, Henke J, Iwata M, Henke L, Tsuji H, Fukunaga T, Ishimoto G,Szekelyi M, Ito S. Novel polymorphisms and haplotypes in the human coagulation factor XIII A-subunit gene. Hum. Genet. 1996; 98: 393-5.
14. Mona S, Josdalyne L. Anderson, Dimitri Scarvelis, Steven P. Doucette, France Gagnon, Philip S. Wells. Factor XIII Val34Leu variant and the risk of myocardial infarction. Thromb. Haemost. 2007; 97: 635-41.
15. Kohler HP, Max H, Ossei Gerning N, Carter A, Mikkola H, Grant PJ.Association of a common polymorphism in factor XIII gene with myocardial infarction. Thromb. Haemost. 1998; 79(1): 8-13
16. Kangsadalampai S, Board PG The Val34Leu polymorphism in the A subunit of coagulation actor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood 1998; 92(8): 2766-70.
17. Franco RF, Pazin-Filho A, Tavella MH, Simoes MV, Marin-Neto JA, Zago MA.Factor XIII val341eu and the risk of myocardial infarction. Haematologica 2000;85:67-71.
18. Butt C, Zheng H, Randell E, Robb D, Parfrey P, Xie YG Combined carrier status of prothrombin 20210A and factor XIII-A Leu34 alleles as a strong risk factor for myocardial infarction: evidence of a gene-gene interaction. Blood 2003; 101: 3037-41.
19. Roldan V, Corral J, Matin F, Rivera J, Pineda J, Gonz(?)lez-Conejero R, Sogorb F, Vicente V. Role of factor XIII Val34Leu polymorphism in patients <45 years of age with acute myocardial infarction. Am. J. Cardiol. 2003; 91: 1242-45.
20. Reiner AP, Heckbert SR, Vos HL, Ariens RA, Lemaitre RN, Smith NL, Lumley T, Rea TD, Hindorff LA, Schellenbaum GD, Rosendaal FR, Siscovick DS,Psaty BM. Genetic variants of coagulation factor XIII, postmenopausal estrogen therapy, and risk of nonfatal myocardial infarction. Blood 2003; 102:25-30.
21. Doggen CJ, Reiner AP, Vos HL, Rosendaal FR. Two factor XIII gene polymorphisms associated with a structural and functional defect and the risk of myocardial infarction in men. J Thrornb. Haemost. 2003; 1: 2056-58
22. Catto AJ, Kohler HP, Bannan S, Stickland M, Carter A, Grant PJ. Factor XIII Val 34 Leu a novel association with primary intracerebral hemorrhage. Stroke 1998; 29: 813-6.
23. Gemmati D, Serino ML, Ongaro A, Tognazzo S, Moratelli S, Resca R, Moretti M, Scapoli GL. A common mutation in the gene for coagulation factor XIII-A (Val34Leu): a risk factor for primary intracerebral hemorrhage is protective against atherothrombotic diseases. Am. J. Hematol. 2001; 67: 183-8.
24. He J, Gu D, Wu X, Reynolds K, Klag MJ, Whelton PK, Major cause of death among men and women in China. N. ENG J. Med. 2005,353: 1124-34.
25. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J,Moy C, Nichol G, O'Donnell CJ, Roger V, Rumsfeld J, Sorlie P, Steinberger J,Thorn T, Wasserthiel-Smoller S, Hong Y. Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115:e69-171.
26. Muszbek L, Yee VC, Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb. Res. 1999; 94: 271-305.
27. Vanhoutte D and Heymans S. Factor XIII: the cement of the heart after myocardial infarction? Eur. Heart. J. 2008; 29: 427-8.
28. Board PG, Webb GC, McKee J, Ichinose A. Localization of the coagulation factor XIII A subunit gene (F13A) to chromosome bands 6p24-p25. Cytogenet.Cell. Genet. 1988; 48: 25-7.
29. Ichinose A, Davie EW. Characterization of the gene for the a subunit of human factor XIII (plasma transglutaminase), a blood coagulation factor. Proc. Natl.Acad. Sci. USA. 1988; 85: 5829-33.
30. Weisberg LJ, Shiu DT, Greenberg CS, Kan YW, Shuman MA. Localization of the gene for coagulation factor XIII a-chain to chromosome 6 and identification of sites of synthesis. J. Clin. Invest. 1987; 79: 649-52.
31. Bereczky ZVZ, Katona E, Muszbek RAL. Factor XIII Val34Leu variant protects against coronary artery Disease. Thromb. Haemost. 2007; 97: 458-63.
32. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadelphia:Lipincott-Raven Publishers, 1998; 9-11.
33. Choudhury I, Marsh JD. Myocardial infarction in young patients. Am. J. Med.1999; 107: 254-61.
34. Kardasz I, De Caterina R. Myocardial infarction with normal coronary arteries: a conundram with multiple aetiologies and variable prognosis: an update. J.Intern. Med. 2007; 261: 330-48.
35. Speidl WS, Nikfardjam M, Niessner A, Jordanova N, Zorn G, Maurer G,Schreiber W, Wojta J, Huber K. Premature compared with late onset of coronary artery disease: young patients show a severe defect in fibrinolytic response to venous occlusion. Blood. Coagul. Fibrinolysis. 2007; 18: 165-71
36. Maitland- an der Z, Bas J.M. P, Amy I. L, Eric B, Donna K. A, Suzanne C,Barry R. D, Catherine L.F, Charles E. F and John H. E. The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13) on the effectiveness of statins: the GenHAT study. Pharmacogenetics and Genomics 2009,19:338-344
37. Nahrendorf M, Hu K, Frantz S, Jaffer FA, Tung CH, Hiller KH, Voll S,Nordbeck P, Sosnovik D, Gattenlohner S, Novikov M, Dickneite G, Reed GL,Jakob P, Rosenzweig A, Bauer WR, Weissleder R, Ertl G Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodelling in mice with myocardial infarction. Circulation 2006; 113:1196-202.
38. Nahrendorf M, Aikawa E, Figueiredo JL, Stangenberg L, van den Borne S,Blankesteijn WM, Sosnovik D, Jaffer FA, Tung CH, Weissleder R.Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodeling: implications for FXIII therapy and antithrombin use in myocardial infarction. Eur. Heart. J. 2008; 29: 445-54. doi:10.1093/eurheartj/ehm558.
39. Nahrendorf M, Weissleder R, Ertl G (2006) Does FXIII deficiency impair wound healing after myocardial infarction? PLoS. ONE. 20; 1: e48.
40. Kohler HP, Futers TS, Grant PJ. Prevalence of three common polymorphisms in the A-subunit gene of factor XIII in patients with coronary artery disease. Thromb Haemost 1999;81:511-5.
41. Gallivan L, Markham AF, Anwar R. The Leu564 factor XIIIA variant results in significantly lower plasma factor XIII levels than the Pro564 variant. Thromb Haemost 1999; 82:1368-70
42. Komanasin N, Futers TS, Ariens RAS, Grant PJ. A novel polymorphism in the factor XIII B subunit (His95Arg) relates to the dissociation of the A2B2 tetramer. Thromb Haemost 1999; 82 (suppl):38.
43. Boekholdt SM, Sandhu MS, Wareham NJ, Luben R, Reitsma PH, Khaw KT.Fibrinogen plasma levels modify the association between the factor XIII Val34Leu variant and risk of coronary artery disease: the EPIC-Norfolk prospective population study. J. Thromb. Haemost. 2006; 4: 2204-09.
44. Kobbervig C, Williams E. FXIII polymorphisms, fibrin clot structure and thrombotic risk. Biophys. Chem. 2004; 112: 223-8.
45. Kohler HP, Mansfield MW, Clark PS, Grant PJ. Interaction between insulin resistance and factor XIII Val34Leu in patients with coronary artery disease.Thromb. Haemost. 1999; 82: 1202-03.
1. Ruggeri ZM: Platelets in Atherothrombosis. Nat Med 2002,8:1227-1234.
2. Huo Y, Ley KF: Role of platelets in the development of atherosclerosis.Trends Cardiovasc Med 2004,14:18-22.
3. Wang TH, Bhatt DL, Topol EJ: Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006, 27:647-54.
4. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB: Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001, 409:202-207
5. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK: Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502.
6. CAPRIE Steering Committee: A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996,348:1329-1339
7. Pierre Fontana, Annabelle Dupont , Sophie, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation, 2003,108: 989-995.2
8. Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, Gaussem P: Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003,108:989-995.
9. Fontana P, Gaussem P, Aiach M, Fiessinger JN, Emmerich J, Reny JL: P2Y12 H2 haplotype is associated with peripheral arterial disease. A case-control study. Circulation 2003, 108:2971-2973.
10. Gunther Hollopeter, Hans-Michael Jantzen, Diana Vincent, et al,Identi(?)cation of the platelet ADP receptor targeted by antithrombotic drugs. Nature,2001,409;202-207
11. Patrick Andre, Suzanne M. Delaney, Thomas LaRocca, at al P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries . J Clin Invest. 2003,112 (3): 398-406
12. U Cavallari, Elisabetta Trabetti, Giovanni Malerba, Michele Biscuola,Domenico Girelli, Oliviero Olivieri, Nicola Martinelli, Dominick J Angiolillo,Roberto Corrocher and Pier Franco Pignatti Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease BMC Medical Genetics 2007, 8:59 doirlO.l 186/1471-2350-8-59
13. Ambrose JA, Barua RS: The pathophysiology of cigarette smoking and cardiovascular disease. An update. J Am Coll Cardiol 2004, 43:1731-1737.
14. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U, Trabetti E, Sabate M, Jimenez-Quevedo P, Hernandez R, Moreno R, Escaned J,Alfonso F, Banuelos C, Costa MA, Bass TA, Pignatti PF, Macaya C: Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res 2005, 116:491-497.
15. von Beckerath N, von Beckerath O, Koch W, Eichinger M, Schomig A,Kastrati A: P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis 2005,16:199-204.
16. Lev El, Patel RT, Guthikonda S, Lopez D, Bray PF, Kleiman NS: Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP Ilia and response to aspirin and clopidogrel. Thromb Res 2007,119:355-60.
17. Smith SM, Judge HM, Peters G, Armstrong M, Fontana P, Gaussem P, Daly ME,Storey RF: Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy.Platelets 2006, 17:250-8.
18. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U,Trabetti E, Sabate M, Hernandez R, Moreno R, Escaned J, Alfonso F, tion of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 2006,26(8): 1895-900.
19. Hetherington SL, Singh RK, Lodwick D, Thompson JR, Goodall AH, Samani NJ: Dimorphism in the P2Y1 ADP Receptor Gene is associated with increased platelet activation response to ADP. Arterioscler Thromb Vasc Biol 2005,25:252-257.
1. Dudman NPB, Hicks C, Lynch JF, et al. Homocysteine thiolactone disposal by human arterial endothelial cells and serum in vitro. Arterioscler Thromb. 1991;11:663-670.
2. Steinhubl SR, Berger PB, Brennan DM, Topol EJ; CREDO Investigators.Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol. 2006; 47:939-943.
3. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol. 2005; 45:1157-1164.
4. Ding Z, Kim S, Dorsam RT, et al. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues,Cysl7 and Cys270. Blood. 2003; 101 :3908-3914.
5. Jackson S.P. The growing complexity of platelet aggregation. Blood, 15 6 2007, 109, (12): 5087-5095
6. O'Donnell CJ, Larson MG, Feng DL, et al. Genetic and environmental contributions to platelet aggregation: the Framingham Heart Study. Circulation.2001; 103: 3051-3056.
7. Kurihara A, Hagihara K, Kazui M, et al. In vitro metabolism of antiplatelet agent clopidogrel: cytochrome P450 isoforms responsible for two oxidation steps involved in the active metabolite formation. Drug Metab Rev. 2005; 37(suppl 2):99.
8. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P-450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008; 51 :1925-1934.
9. Michelson AD, Linden MD, Furman MI, Li Y, Barnard MR, Fox ML, Lau WC,McLaughlin TJ, Frelinger AL. Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'. J Thromb Haemost. 2007;5:75-81.
10. Wiviott SD, Trenk D, Frelinger AL, O'Donaghue M, Neumann F-J, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R,Murphy SA, McCabe CH, Antman EM, Braunwald E. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention. The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation -Thrombolysis in Myocardial Infarction 44 Trial. Circulation. 2007; 116:2923-2932.
11. Cattaneo M. The platelet P2 receptors. In: Michelson AD, ed. Platelets. 2nd ed. San Diego: Elsevier/Academic Press 2007; 201-213.
12. Cattaneo M. ADP receptor antagonists. In: Michelson AD, ed. Platelets. 2nd ed.San Diego: Elsevier/Academic Press 2007; 1127-1144.
13. Sabatine MS, Cannon CP, Gibson CM, L(?)pez-Sendon JL, Montalescot G,Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E;CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005; 352: 1179-1189.
14. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000; 84 :891-896.
15. Sibbing D, Morath T, Braun S, et al. Antiplatelet action of clopidogrel is not influenced by proton pump inhibitors in patients with coronary artery disease under clopidogrel maintainence treatment. Eur Heart J. 2008; 29 (suppl):abstract 832.
16. Muller I, Besta F, Schulz C, et al. Prevalence of clopidogrel nonresponders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003; 89:783-787.
17. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. J Am Coll Cardiol.2008; 51 :256-260.
18. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK;Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA;Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001; 358: 527-533.
19. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G.Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty) study. Circulation. 2005; 111:2099-2106.
20. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345: 494-502.
21. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, Tantry US.Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol. 2005; 46: 1827-1832.
22. Holmes DR Jr, Kereiakes DJ, Laskey WK, Colombo A, Ellis SG, Henry TD,Popma JJ, Serruys PW, Kimura T, Williams DO, Windecker S, Krucoff MW. Thrombosis and drug-eluting stents: an objective appraisal. J Am Coll Cardiol.2007; 50: 109-118.
23. Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D,Topol EJ; Clopidogrel for the Reduction of Events During Observation Investigators. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.Circulation. 2003; 108: 921-924.
24. Wang TH, Bhatt DL, Fox KA, Steinhubl SR, Brennan DM, Hacke W, Mak KH,Pearson TA, Boden WE, Steg PG, Flather MD, Montalescot G, Topol EJ;CHARISMA Investigators. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J. in press
25. Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E,Zenni MM, Guzman LA, Bass TA, Costa MA. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation. 2007; 115: 708-716.
26. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA.Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol. 2007; 49: 657-666.
27. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS;COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366: 1607-1621.
28. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA,Naganuma H, Siegbahn A, Wallentin L. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006; 27: 1166-1173.
29. Bonello L, Paganelli F, Arpin-Bomet M, Auquier P, Sampol J, Dignat-George F,Barragan P, Camoin-Jau L. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost. 2007; 5: 1630-1636.
30. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost. 2005; 3: 85-92.
31. Agarwal S, Coakely M, Reddy K, et al. Quantifying the effect of antiplatelet therapy: a comparison of the platelet function analyzer (PFA-100) and modified thromboelastography (mTEG) with light transmission platelet aggregometry.Anesthesiology. 2006; 105: 676-683.
32. Gurbel PA, Lau WC, Tantry US. Omeprazole: a possible new candidate influencing the anti-platelet effect of clopidogrel. J Am Coll Cardiol.2008;51:261-263.
33. Schwarz UR, Geiger J, Walter U, Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets-definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost. 1999; 82:1145-1152.
34. Michelson AD, Frelinger AL, Furman MI. Resistance to antiplatelet drugs. Eur Heart J Suppl. 2006; 8 (suppl G): G53-G58.
35. 35. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction.Circulation. 2003; 107 :32-37.
36. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J. 2006; 27 :647-654.
37. Montalescot G, Sideris G, Meuleman C, Bal-dit-Sollier C, Lellouche N, Steg PG,Slama M, Milleron O, Collet JP, Henry P, Beygui F, Drouet L; ALBION Trial Investigators. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol. 2006;48:931-938.
38. Cavallari U, Trabetti E, Malerba G, et al. Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease. BMC Med Genetics. 2007; 8 :59.
39. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos.2003; 31 :53-59.
40. Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007; 81 :735-741.
41. Giusti B, Gori AM, Marcucci R, et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual anti-platelet treatment in high-risk vascular patients. Pharmacogenet Genomics. 2007; 17:1057-1064.
42. Hulot JS, Bura A, Villani E, et al. Cytochrome P450 2C19 loss of function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006; 108 :2244-2247.
43. Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, Guyer KE,Tait AR, Bates ER. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004; 109:166-171.
44. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009; 360: 354-362.
45. Taubert D, Kastrati A, Harlfinger S, et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost. 2004; 92 : 311-316.
46. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB III,Morrison DA, O'Neill WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF,Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006;113: 156-175.
47. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, Bonnet JL,Alessi MC. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost. 2006; 4: 542-549.
48. Von Beckerath N, Kastrati A, Wieczorek A, Pogatsa-Murray G, Sibbing D, Graf I, Schomig A. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J. 2007; 28: 1814-1819.
49. von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A,Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-,and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation. 2005; 112:2946-2950.
50. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Barrera-Ramirez C,Sabate M, Hernandez R, Moreno R, Escaned J, Alfonso F, Bafiuelos C, Costa MA, Bass TA, Macaya C. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res.2005; 115:101-108.
51. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vase Biol. 2004; 24: 1980-1987.
52. Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after a 600mg loading dose of clopidogrel in a large unselected cohort of candidates for percutaneous coronary intervention. Circulation.2005; 111:2560-2564.
53. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I,Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004; 109: 3171-3175.
54. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, Gick M, Caputo A, Buttner HJ, Neumann FJ. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol. 2006;48: 1742-1750.
55. Payne CD, Li YG, Small DS, Ernest CS, Farid NA, Jakubowski JA, Brandt JT,Salazar D, Winters KJ. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol.
56. Samara WM, Bliden KP, Tantry US, Gurbel PA. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb Res.2005; 115: 89-94.
57. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003; 107: 2908-2913.
58. Cuisset T, Frere C, Quilici J, et al. Role of the T744C polymorphism of the P2Y12 gene on platelet responsiveness to a 600-mg loading dose of clodigrel in 597 patients with non-ST segment elevation acute coronary syndrome. Thromb Res. 2007; 120 :893-899.
59. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12 receptor mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008; 29 :21-30.
60. Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E;JUMBO-TIMI 26 Investigators. Randomized comparison of prasugrel (CS-747,LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation.2005; 111: 3366-3373.
61. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357 :2001-2015.
62. Niitsu Y, Jakubowski JA, Sugidachi A, Asai F. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost. 2005; 31: 184-194.
63. Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS,Jakubowski JA, Naganuma H, Winters KJ. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007; 153: 66.
64. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G.Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006; 27: 1038-1047.
65. Cannon CP, Husted S, Storey RF, Harrington RA, Watkins C, Hill S. The DISPERSE2 trial: safety, tolerability and preliminary efficacy of AZD6140, the first oral reversible ADP receptor antagonist compared with clopidogrel in patients with non-ST elevation acute coronary syndrome. Presented at: 78th American Heart Association Scientific Sessions; November 13-16, 2005; Dallas,TX. Abstract 2906.
66. Van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost. 2005; 31:195-204.
67. Greenbaum AB, Grines CL, Bittl JA, Becker RC, Kereiakes DJ, Gilchrist IC,Clegg J, Stankowski JE, Grogan DR, Harrington RA, Emanuelsson H, Weaver WD. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part,phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J. 2006; 151: 689.
68. Gretler DD, Conley PB, Andre P, Jurek M, Pandey A, Ronanko K, Leese PT,Hutchaleelaha A, Phillips DR. "First in human" experience with PRT060128, a new direct-acting, reversible, P2Y_(12) inhibitor for IV and oral use. J Am Coll Cardiol. 2007; 49 [9 (suppl 2)]: 326A.
2. Mikkola H, Syrjala M, Rasi V, Vahtera E, Hamalainen E, Peltonen L, Palotie A.Deficiency in the A-subunit of coagulation factor XIII: two novel point mutations demonstrate different effects on transcript levels. Blood. 1994; 84:517-25.
3. Balogh I, Szoke G, Karpati L, Wartiovaara U, Katona E, Komaromi I,Haramura G, Pfliegler G, Mikkola H, Muszbek L. Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia.Blood 2000; 96:2479-86.
4. Wartiovaara U, Mikkola H, Szoke G, Haramura G, Karpati L, Balogh I, Lassila R, Muszbek L, Palotie A. Effect of Val34Leu polymorphism on the activation of the coagulation factor XIII-A. Thromb Haemost 2000; 84: 595-600.
5. Ariens RA, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96: 988-95.
6. Lim BC, Ariens RA, Carter AM, Weisel JW, Grant PJ. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 2003; 361: 1424-31.
7. Lorand L, Losowsky MS, Miloszewski KJ. Human factor XIII:fibrin-stabilizing factor. Prog. Hemost. Thromb. 1980; 5:245-90.
8. Polgar J, Hidasi V, Muszbek L. Non-proteolytic activation of cellular protransglutaminase (placenta macrophage factor XIII). Biochem. J. 1990; 267:557-60.
9. Schwartz ML, Pizzo SV, Hill RL, McKee PA. Human factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and crosslinking of fibrinogen and fibrin. J. Biol. Chem. 1973; 248: 1395-407
10. Loukianos S. Rallidis, Marianna Politou, Christoforos Komporozos,Demosthenes B. Panagiotakos, Chrisoula I. Belessi, Anthi Travlou, John Lekakis, Dimitrios T. Kremastinos. Factor XIII Val34Leu polymorphism and the risk of myocardial infarction under the age of 36 years. Thromb. Haemost.2008; 99: 1085-9
11. Aleksic N, Ahn C, Wang YW. Factor XIIIA Val34Leu polymorphism does not predict risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler. Thromb. Vasc. Biol. 2002; 22:348-52.
12. Cho KH, Kim BC, Kim MK, Shin BA. No Association of Factor XIII Val34Leu Polymorphism with Primary Intracerebral Hemorrhage and Healthy Controls in Korean Population. J. Korean. Med. Sci. 2002; 17: 249-53.
13. Suzuki K, Henke J, Iwata M, Henke L, Tsuji H, Fukunaga T, Ishimoto G,Szekelyi M, Ito S. Novel polymorphisms and haplotypes in the human coagulation factor XIII A-subunit gene. Hum. Genet. 1996; 98: 393-5.
14. Mona S, Josdalyne L. Anderson, Dimitri Scarvelis, Steven P. Doucette, France Gagnon, Philip S. Wells. Factor XIII Val34Leu variant and the risk of myocardial infarction. Thromb. Haemost. 2007; 97: 635-41.
15. Kohler HP, Max H, Ossei Gerning N, Carter A, Mikkola H, Grant PJ.Association of a common polymorphism in factor XIII gene with myocardial infarction. Thromb. Haemost. 1998; 79(1): 8-13
16. Kangsadalampai S, Board PG The Val34Leu polymorphism in the A subunit of coagulation actor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood 1998; 92(8): 2766-70.
17. Franco RF, Pazin-Filho A, Tavella MH, Simoes MV, Marin-Neto JA, Zago MA.Factor XIII val341eu and the risk of myocardial infarction. Haematologica 2000;85:67-71.
18. Butt C, Zheng H, Randell E, Robb D, Parfrey P, Xie YG Combined carrier status of prothrombin 20210A and factor XIII-A Leu34 alleles as a strong risk factor for myocardial infarction: evidence of a gene-gene interaction. Blood 2003; 101: 3037-41.
19. Roldan V, Corral J, Matin F, Rivera J, Pineda J, Gonz(?)lez-Conejero R, Sogorb F, Vicente V. Role of factor XIII Val34Leu polymorphism in patients <45 years of age with acute myocardial infarction. Am. J. Cardiol. 2003; 91: 1242-45.
20. Reiner AP, Heckbert SR, Vos HL, Ariens RA, Lemaitre RN, Smith NL, Lumley T, Rea TD, Hindorff LA, Schellenbaum GD, Rosendaal FR, Siscovick DS,Psaty BM. Genetic variants of coagulation factor XIII, postmenopausal estrogen therapy, and risk of nonfatal myocardial infarction. Blood 2003; 102:25-30.
21. Doggen CJ, Reiner AP, Vos HL, Rosendaal FR. Two factor XIII gene polymorphisms associated with a structural and functional defect and the risk of myocardial infarction in men. J Thrornb. Haemost. 2003; 1: 2056-58
22. Catto AJ, Kohler HP, Bannan S, Stickland M, Carter A, Grant PJ. Factor XIII Val 34 Leu a novel association with primary intracerebral hemorrhage. Stroke 1998; 29: 813-6.
23. Gemmati D, Serino ML, Ongaro A, Tognazzo S, Moratelli S, Resca R, Moretti M, Scapoli GL. A common mutation in the gene for coagulation factor XIII-A (Val34Leu): a risk factor for primary intracerebral hemorrhage is protective against atherothrombotic diseases. Am. J. Hematol. 2001; 67: 183-8.
24. He J, Gu D, Wu X, Reynolds K, Klag MJ, Whelton PK, Major cause of death among men and women in China. N. ENG J. Med. 2005,353: 1124-34.
25. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J,Moy C, Nichol G, O'Donnell CJ, Roger V, Rumsfeld J, Sorlie P, Steinberger J,Thorn T, Wasserthiel-Smoller S, Hong Y. Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115:e69-171.
26. Muszbek L, Yee VC, Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb. Res. 1999; 94: 271-305.
27. Vanhoutte D and Heymans S. Factor XIII: the cement of the heart after myocardial infarction? Eur. Heart. J. 2008; 29: 427-8.
28. Board PG, Webb GC, McKee J, Ichinose A. Localization of the coagulation factor XIII A subunit gene (F13A) to chromosome bands 6p24-p25. Cytogenet.Cell. Genet. 1988; 48: 25-7.
29. Ichinose A, Davie EW. Characterization of the gene for the a subunit of human factor XIII (plasma transglutaminase), a blood coagulation factor. Proc. Natl.Acad. Sci. USA. 1988; 85: 5829-33.
30. Weisberg LJ, Shiu DT, Greenberg CS, Kan YW, Shuman MA. Localization of the gene for coagulation factor XIII a-chain to chromosome 6 and identification of sites of synthesis. J. Clin. Invest. 1987; 79: 649-52.
31. Bereczky ZVZ, Katona E, Muszbek RAL. Factor XIII Val34Leu variant protects against coronary artery Disease. Thromb. Haemost. 2007; 97: 458-63.
32. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadelphia:Lipincott-Raven Publishers, 1998; 9-11.
33. Choudhury I, Marsh JD. Myocardial infarction in young patients. Am. J. Med.1999; 107: 254-61.
34. Kardasz I, De Caterina R. Myocardial infarction with normal coronary arteries: a conundram with multiple aetiologies and variable prognosis: an update. J.Intern. Med. 2007; 261: 330-48.
35. Speidl WS, Nikfardjam M, Niessner A, Jordanova N, Zorn G, Maurer G,Schreiber W, Wojta J, Huber K. Premature compared with late onset of coronary artery disease: young patients show a severe defect in fibrinolytic response to venous occlusion. Blood. Coagul. Fibrinolysis. 2007; 18: 165-71
36. Maitland- an der Z, Bas J.M. P, Amy I. L, Eric B, Donna K. A, Suzanne C,Barry R. D, Catherine L.F, Charles E. F and John H. E. The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13) on the effectiveness of statins: the GenHAT study. Pharmacogenetics and Genomics 2009,19:338-344
37. Nahrendorf M, Hu K, Frantz S, Jaffer FA, Tung CH, Hiller KH, Voll S,Nordbeck P, Sosnovik D, Gattenlohner S, Novikov M, Dickneite G, Reed GL,Jakob P, Rosenzweig A, Bauer WR, Weissleder R, Ertl G Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodelling in mice with myocardial infarction. Circulation 2006; 113:1196-202.
38. Nahrendorf M, Aikawa E, Figueiredo JL, Stangenberg L, van den Borne S,Blankesteijn WM, Sosnovik D, Jaffer FA, Tung CH, Weissleder R.Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodeling: implications for FXIII therapy and antithrombin use in myocardial infarction. Eur. Heart. J. 2008; 29: 445-54. doi:10.1093/eurheartj/ehm558.
39. Nahrendorf M, Weissleder R, Ertl G (2006) Does FXIII deficiency impair wound healing after myocardial infarction? PLoS. ONE. 20; 1: e48.
40. Kohler HP, Futers TS, Grant PJ. Prevalence of three common polymorphisms in the A-subunit gene of factor XIII in patients with coronary artery disease. Thromb Haemost 1999;81:511-5.
41. Gallivan L, Markham AF, Anwar R. The Leu564 factor XIIIA variant results in significantly lower plasma factor XIII levels than the Pro564 variant. Thromb Haemost 1999; 82:1368-70
42. Komanasin N, Futers TS, Ariens RAS, Grant PJ. A novel polymorphism in the factor XIII B subunit (His95Arg) relates to the dissociation of the A2B2 tetramer. Thromb Haemost 1999; 82 (suppl):38.
43. Boekholdt SM, Sandhu MS, Wareham NJ, Luben R, Reitsma PH, Khaw KT.Fibrinogen plasma levels modify the association between the factor XIII Val34Leu variant and risk of coronary artery disease: the EPIC-Norfolk prospective population study. J. Thromb. Haemost. 2006; 4: 2204-09.
44. Kobbervig C, Williams E. FXIII polymorphisms, fibrin clot structure and thrombotic risk. Biophys. Chem. 2004; 112: 223-8.
45. Kohler HP, Mansfield MW, Clark PS, Grant PJ. Interaction between insulin resistance and factor XIII Val34Leu in patients with coronary artery disease.Thromb. Haemost. 1999; 82: 1202-03.
1. Ruggeri ZM: Platelets in Atherothrombosis. Nat Med 2002,8:1227-1234.
2. Huo Y, Ley KF: Role of platelets in the development of atherosclerosis.Trends Cardiovasc Med 2004,14:18-22.
3. Wang TH, Bhatt DL, Topol EJ: Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006, 27:647-54.
4. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB: Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001, 409:202-207
5. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK: Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502.
6. CAPRIE Steering Committee: A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996,348:1329-1339
7. Pierre Fontana, Annabelle Dupont , Sophie, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation, 2003,108: 989-995.2
8. Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, Gaussem P: Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003,108:989-995.
9. Fontana P, Gaussem P, Aiach M, Fiessinger JN, Emmerich J, Reny JL: P2Y12 H2 haplotype is associated with peripheral arterial disease. A case-control study. Circulation 2003, 108:2971-2973.
10. Gunther Hollopeter, Hans-Michael Jantzen, Diana Vincent, et al,Identi(?)cation of the platelet ADP receptor targeted by antithrombotic drugs. Nature,2001,409;202-207
11. Patrick Andre, Suzanne M. Delaney, Thomas LaRocca, at al P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries . J Clin Invest. 2003,112 (3): 398-406
12. U Cavallari, Elisabetta Trabetti, Giovanni Malerba, Michele Biscuola,Domenico Girelli, Oliviero Olivieri, Nicola Martinelli, Dominick J Angiolillo,Roberto Corrocher and Pier Franco Pignatti Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease BMC Medical Genetics 2007, 8:59 doirlO.l 186/1471-2350-8-59
13. Ambrose JA, Barua RS: The pathophysiology of cigarette smoking and cardiovascular disease. An update. J Am Coll Cardiol 2004, 43:1731-1737.
14. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U, Trabetti E, Sabate M, Jimenez-Quevedo P, Hernandez R, Moreno R, Escaned J,Alfonso F, Banuelos C, Costa MA, Bass TA, Pignatti PF, Macaya C: Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res 2005, 116:491-497.
15. von Beckerath N, von Beckerath O, Koch W, Eichinger M, Schomig A,Kastrati A: P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis 2005,16:199-204.
16. Lev El, Patel RT, Guthikonda S, Lopez D, Bray PF, Kleiman NS: Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP Ilia and response to aspirin and clopidogrel. Thromb Res 2007,119:355-60.
17. Smith SM, Judge HM, Peters G, Armstrong M, Fontana P, Gaussem P, Daly ME,Storey RF: Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy.Platelets 2006, 17:250-8.
18. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U,Trabetti E, Sabate M, Hernandez R, Moreno R, Escaned J, Alfonso F, tion of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 2006,26(8): 1895-900.
19. Hetherington SL, Singh RK, Lodwick D, Thompson JR, Goodall AH, Samani NJ: Dimorphism in the P2Y1 ADP Receptor Gene is associated with increased platelet activation response to ADP. Arterioscler Thromb Vasc Biol 2005,25:252-257.
1. Dudman NPB, Hicks C, Lynch JF, et al. Homocysteine thiolactone disposal by human arterial endothelial cells and serum in vitro. Arterioscler Thromb. 1991;11:663-670.
2. Steinhubl SR, Berger PB, Brennan DM, Topol EJ; CREDO Investigators.Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol. 2006; 47:939-943.
3. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol. 2005; 45:1157-1164.
4. Ding Z, Kim S, Dorsam RT, et al. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues,Cysl7 and Cys270. Blood. 2003; 101 :3908-3914.
5. Jackson S.P. The growing complexity of platelet aggregation. Blood, 15 6 2007, 109, (12): 5087-5095
6. O'Donnell CJ, Larson MG, Feng DL, et al. Genetic and environmental contributions to platelet aggregation: the Framingham Heart Study. Circulation.2001; 103: 3051-3056.
7. Kurihara A, Hagihara K, Kazui M, et al. In vitro metabolism of antiplatelet agent clopidogrel: cytochrome P450 isoforms responsible for two oxidation steps involved in the active metabolite formation. Drug Metab Rev. 2005; 37(suppl 2):99.
8. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P-450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008; 51 :1925-1934.
9. Michelson AD, Linden MD, Furman MI, Li Y, Barnard MR, Fox ML, Lau WC,McLaughlin TJ, Frelinger AL. Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'. J Thromb Haemost. 2007;5:75-81.
10. Wiviott SD, Trenk D, Frelinger AL, O'Donaghue M, Neumann F-J, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R,Murphy SA, McCabe CH, Antman EM, Braunwald E. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention. The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation -Thrombolysis in Myocardial Infarction 44 Trial. Circulation. 2007; 116:2923-2932.
11. Cattaneo M. The platelet P2 receptors. In: Michelson AD, ed. Platelets. 2nd ed. San Diego: Elsevier/Academic Press 2007; 201-213.
12. Cattaneo M. ADP receptor antagonists. In: Michelson AD, ed. Platelets. 2nd ed.San Diego: Elsevier/Academic Press 2007; 1127-1144.
13. Sabatine MS, Cannon CP, Gibson CM, L(?)pez-Sendon JL, Montalescot G,Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E;CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005; 352: 1179-1189.
14. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000; 84 :891-896.
15. Sibbing D, Morath T, Braun S, et al. Antiplatelet action of clopidogrel is not influenced by proton pump inhibitors in patients with coronary artery disease under clopidogrel maintainence treatment. Eur Heart J. 2008; 29 (suppl):abstract 832.
16. Muller I, Besta F, Schulz C, et al. Prevalence of clopidogrel nonresponders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003; 89:783-787.
17. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. J Am Coll Cardiol.2008; 51 :256-260.
18. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK;Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA;Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001; 358: 527-533.
19. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G.Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty) study. Circulation. 2005; 111:2099-2106.
20. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345: 494-502.
21. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, Tantry US.Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol. 2005; 46: 1827-1832.
22. Holmes DR Jr, Kereiakes DJ, Laskey WK, Colombo A, Ellis SG, Henry TD,Popma JJ, Serruys PW, Kimura T, Williams DO, Windecker S, Krucoff MW. Thrombosis and drug-eluting stents: an objective appraisal. J Am Coll Cardiol.2007; 50: 109-118.
23. Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D,Topol EJ; Clopidogrel for the Reduction of Events During Observation Investigators. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.Circulation. 2003; 108: 921-924.
24. Wang TH, Bhatt DL, Fox KA, Steinhubl SR, Brennan DM, Hacke W, Mak KH,Pearson TA, Boden WE, Steg PG, Flather MD, Montalescot G, Topol EJ;CHARISMA Investigators. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J. in press
25. Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E,Zenni MM, Guzman LA, Bass TA, Costa MA. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation. 2007; 115: 708-716.
26. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA.Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol. 2007; 49: 657-666.
27. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS;COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366: 1607-1621.
28. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA,Naganuma H, Siegbahn A, Wallentin L. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006; 27: 1166-1173.
29. Bonello L, Paganelli F, Arpin-Bomet M, Auquier P, Sampol J, Dignat-George F,Barragan P, Camoin-Jau L. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost. 2007; 5: 1630-1636.
30. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost. 2005; 3: 85-92.
31. Agarwal S, Coakely M, Reddy K, et al. Quantifying the effect of antiplatelet therapy: a comparison of the platelet function analyzer (PFA-100) and modified thromboelastography (mTEG) with light transmission platelet aggregometry.Anesthesiology. 2006; 105: 676-683.
32. Gurbel PA, Lau WC, Tantry US. Omeprazole: a possible new candidate influencing the anti-platelet effect of clopidogrel. J Am Coll Cardiol.2008;51:261-263.
33. Schwarz UR, Geiger J, Walter U, Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets-definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost. 1999; 82:1145-1152.
34. Michelson AD, Frelinger AL, Furman MI. Resistance to antiplatelet drugs. Eur Heart J Suppl. 2006; 8 (suppl G): G53-G58.
35. 35. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction.Circulation. 2003; 107 :32-37.
36. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J. 2006; 27 :647-654.
37. Montalescot G, Sideris G, Meuleman C, Bal-dit-Sollier C, Lellouche N, Steg PG,Slama M, Milleron O, Collet JP, Henry P, Beygui F, Drouet L; ALBION Trial Investigators. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol. 2006;48:931-938.
38. Cavallari U, Trabetti E, Malerba G, et al. Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease. BMC Med Genetics. 2007; 8 :59.
39. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos.2003; 31 :53-59.
40. Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007; 81 :735-741.
41. Giusti B, Gori AM, Marcucci R, et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual anti-platelet treatment in high-risk vascular patients. Pharmacogenet Genomics. 2007; 17:1057-1064.
42. Hulot JS, Bura A, Villani E, et al. Cytochrome P450 2C19 loss of function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006; 108 :2244-2247.
43. Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, Guyer KE,Tait AR, Bates ER. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004; 109:166-171.
44. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009; 360: 354-362.
45. Taubert D, Kastrati A, Harlfinger S, et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost. 2004; 92 : 311-316.
46. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB III,Morrison DA, O'Neill WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF,Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006;113: 156-175.
47. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, Bonnet JL,Alessi MC. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost. 2006; 4: 542-549.
48. Von Beckerath N, Kastrati A, Wieczorek A, Pogatsa-Murray G, Sibbing D, Graf I, Schomig A. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J. 2007; 28: 1814-1819.
49. von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A,Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-,and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation. 2005; 112:2946-2950.
50. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Barrera-Ramirez C,Sabate M, Hernandez R, Moreno R, Escaned J, Alfonso F, Bafiuelos C, Costa MA, Bass TA, Macaya C. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res.2005; 115:101-108.
51. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vase Biol. 2004; 24: 1980-1987.
52. Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after a 600mg loading dose of clopidogrel in a large unselected cohort of candidates for percutaneous coronary intervention. Circulation.2005; 111:2560-2564.
53. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I,Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004; 109: 3171-3175.
54. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, Gick M, Caputo A, Buttner HJ, Neumann FJ. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol. 2006;48: 1742-1750.
55. Payne CD, Li YG, Small DS, Ernest CS, Farid NA, Jakubowski JA, Brandt JT,Salazar D, Winters KJ. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol.
56. Samara WM, Bliden KP, Tantry US, Gurbel PA. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb Res.2005; 115: 89-94.
57. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003; 107: 2908-2913.
58. Cuisset T, Frere C, Quilici J, et al. Role of the T744C polymorphism of the P2Y12 gene on platelet responsiveness to a 600-mg loading dose of clodigrel in 597 patients with non-ST segment elevation acute coronary syndrome. Thromb Res. 2007; 120 :893-899.
59. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12 receptor mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008; 29 :21-30.
60. Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E;JUMBO-TIMI 26 Investigators. Randomized comparison of prasugrel (CS-747,LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation.2005; 111: 3366-3373.
61. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357 :2001-2015.
62. Niitsu Y, Jakubowski JA, Sugidachi A, Asai F. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost. 2005; 31: 184-194.
63. Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS,Jakubowski JA, Naganuma H, Winters KJ. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007; 153: 66.
64. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G.Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006; 27: 1038-1047.
65. Cannon CP, Husted S, Storey RF, Harrington RA, Watkins C, Hill S. The DISPERSE2 trial: safety, tolerability and preliminary efficacy of AZD6140, the first oral reversible ADP receptor antagonist compared with clopidogrel in patients with non-ST elevation acute coronary syndrome. Presented at: 78th American Heart Association Scientific Sessions; November 13-16, 2005; Dallas,TX. Abstract 2906.
66. Van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost. 2005; 31:195-204.
67. Greenbaum AB, Grines CL, Bittl JA, Becker RC, Kereiakes DJ, Gilchrist IC,Clegg J, Stankowski JE, Grogan DR, Harrington RA, Emanuelsson H, Weaver WD. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part,phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J. 2006; 151: 689.
68. Gretler DD, Conley PB, Andre P, Jurek M, Pandey A, Ronanko K, Leese PT,Hutchaleelaha A, Phillips DR. "First in human" experience with PRT060128, a new direct-acting, reversible, P2Y_(12) inhibitor for IV and oral use. J Am Coll Cardiol. 2007; 49 [9 (suppl 2)]: 326A.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |